In post-menopausal type 2 diabetic women with NAFLD and significant fibrosis, sclerostin levels were also higher than those of type 2 diabetic patients without NAFLD (27). This evidence concerns the gene SOST and metabolic dysfunction-associated steatotic liver disease.